BRAFTOVI in combination with cetuximab and mFOLFOX6 had previously received accelerated approval in December 2024 based on objective response rate (ORR) results
Asahi Kasei Pharma receives worldwide exclusive rights for the research, development, manufacturing, and marketing of the active ingredients
Asahi Kasei is consistently pursuing its strategy of building a focused, sustainable specialty pharmaceutical platform for immunocompromised and medically complex patient groups
The Phase 2 trial, conducted through Starton’s Sargon Site Network, is expanding from two to six sites across the U.S.
The study is a collaboration between AIM, AstraZeneca, and Erasmus Medical Center in the Netherlands
The move follows encouraging Phase I data and a series of regulatory wins from the U.S. Food and Drug Administration
The collaboration merges biomodal’s 5-base and 6-base sequencing solutions, duet +modC and duet evoC
The study will test the company’s lead product, ZI-MA4-1, in patients with advanced solid cancers
The decision follows compelling data from the AMPLIFY Phase III trial, demonstrating that 77% of patients receiving the Calquence-venetoclax combination were progression-free at three years
Both non-transfusion-dependent and transfusion dependent cohorts met their respective primary and secondary endpoints
Subscribe To Our Newsletter & Stay Updated
